Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Circulating miRNA markers show promise as new prognosticators for multiple myeloma.

Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, Guan J, Benson DM, Efebera YA, Talabere T, Dirisala V, Smith EM, Omedè P, Isaia G, De Luca L, Rossi D, Gentili S, Uccello G, Consiglio J, Ria R, Benevolo G, Bringhen S, Callea V, Weiss B, Ferro A, Magarotto V, Alder H, Byrd JC, Boccadoro M, Marcucci G, Palumbo A, Pichiorri F.

Leukemia. 2014 Sep;28(9):1922-6. doi: 10.1038/leu.2014.155. Epub 2014 May 12. No abstract available.

2.

The potential of miRNAs as biomarkers for multiple myeloma.

Rocci A, Hofmeister CC, Pichiorri F.

Expert Rev Mol Diagn. 2014 Nov;14(8):947-59. doi: 10.1586/14737159.2014.946906. Epub 2014 Aug 7. Review.

PMID:
25098410
3.

The role of circulating miRNAs in multiple myeloma.

Zhang J, Xiao X, Liu J.

Sci China Life Sci. 2015 Dec;58(12):1262-9. doi: 10.1007/s11427-015-4969-2. Epub 2015 Nov 25. Review.

PMID:
26607481
4.

MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma.

Li F, Xu Y, Deng S, Li Z, Zou D, Yi S, Sui W, Hao M, Qiu L.

Oncotarget. 2015 Nov 10;6(35):38270-82. doi: 10.18632/oncotarget.5681.

5.

Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation.

de Larrea CF, Navarro A, Tejero R, Tovar N, Díaz T, Cibeira MT, Rosiñol L, Ferrer G, Rovira M, Rozman M, Monzó M, Bladé J.

Clin Cancer Res. 2012 Jul 1;18(13):3697-704. doi: 10.1158/1078-0432.CCR-12-0191. Epub 2012 Apr 26.

6.

MYEOV is a prognostic factor in multiple myeloma.

Moreaux J, Hose D, Bonnefond A, Reme T, Robert N, Goldschmidt H, Klein B.

Exp Hematol. 2010 Dec;38(12):1189-1198.e3. doi: 10.1016/j.exphem.2010.09.002. Epub 2010 Sep 18.

7.

Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.

Bi C, Chung TH, Huang G, Zhou J, Yan J, Ahmann GJ, Fonseca R, Chng WJ.

Oncotarget. 2015 Sep 22;6(28):26508-18. doi: 10.18632/oncotarget.4769.

8.

The prognostic significance of 8p21 deletion in multiple myeloma.

Sutlu T, Alici E, Jansson M, Wallblom A, Dilber MS, Gahrton G, Nahi H.

Br J Haematol. 2009 Jan;144(2):266-8. doi: 10.1111/j.1365-2141.2008.07454.x. Epub 2008 Nov 11. No abstract available.

PMID:
19016723
9.

Aberrant microRNA expression in multiple myeloma.

Dimopoulos K, Gimsing P, Grønbæk K.

Eur J Haematol. 2013 Aug;91(2):95-105. doi: 10.1111/ejh.12124. Epub 2013 Jun 5. Review.

PMID:
23586898
10.

Clinical significance of TP53 mutation in myeloma.

Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E, Henderson K, Oken M, Van Ness B, Greipp P, Rajkumar SV, Fonseca R.

Leukemia. 2007 Mar;21(3):582-4. Epub 2007 Jan 11. No abstract available.

PMID:
17215851
11.

Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma.

Chang H, Ning Y, Qi X, Yeung J, Xu W.

Br J Haematol. 2007 Oct;139(1):51-4.

PMID:
17854306
12.

MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma.

Gao X, Zhang R, Qu X, Zhao M, Zhang S, Wu H, Jianyong L, Chen L.

Leuk Res. 2012 Dec;36(12):1505-9. doi: 10.1016/j.leukres.2012.08.021. Epub 2012 Sep 7.

PMID:
22959509
13.

Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.

Chen MH, Qi C, Reece D, Chang H.

Hum Pathol. 2012 Jun;43(6):858-64. doi: 10.1016/j.humpath.2011.07.013. Epub 2011 Nov 1.

PMID:
22047644
14.

Genetic variants in the P2RX7 gene are associated with risk of multiple myeloma.

Vangsted AJ, Klausen TW, Gimsing P, Abildgaard N, Andersen NF, Gang AO, Holmström M, Gregersen H, Vogel U, Schwarz P, Jørgensen NR.

Eur J Haematol. 2014 Aug;93(2):172-4. doi: 10.1111/ejh.12353. Epub 2014 May 17. No abstract available.

PMID:
24766221
15.

Serum miR-29a as a marker of multiple myeloma.

Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R.

Leuk Lymphoma. 2013 Jan;54(1):189-91. doi: 10.3109/10428194.2012.704030. Epub 2012 Aug 14. No abstract available.

PMID:
22712836
16.

Impact of genetic abnormalities on the prognoses and clinical parameters of patients with multiple myeloma.

Jekarl DW, Min CK, Kwon A, Kim H, Chae H, Kim M, Lim J, Kim Y, Han K.

Ann Lab Med. 2013 Jul;33(4):248-54. doi: 10.3343/alm.2013.33.4.248. Epub 2013 Jun 24.

17.

MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.

Lazareth A, Song XY, Coquin A, Harel S, Karlin L, Belhadj K, Roos-Weil D, Frenzel L, Tamburini J, Macro M, Chevret S, Loiseau HA, Minvielle S, Fermand JP, Soulier J, Bories JC, Arnulf B.

Haematologica. 2015 Nov;100(11):e471-4. doi: 10.3324/haematol.2015.127001. Epub 2015 Jul 23. No abstract available.

18.

The impact of race on outcomes of autologous transplantation in patients with multiple myeloma.

Verma PS, Howard RS, Weiss BM.

Am J Hematol. 2008 May;83(5):355-8. doi: 10.1002/ajh.21139.

19.

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.

Nair B, Shaughnessy JD Jr, Zhou Y, Astrid-Cartron M, Qu P, van Rhee F, Anaissie E, Alsayed Y, Waheed S, Hollmig K, Szymonifka J, Petty N, Hoering A, Barlogie B.

Blood. 2009 Jun 25;113(26):6572-5. doi: 10.1182/blood-2009-02-207803. Epub 2009 Apr 23.

20.

[MicroRNA and multiple myeloma].

Li CM, Chen LJ, Li JY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Feb;19(1):244-8. Review. Chinese.

PMID:
21362262

Supplemental Content

Support Center